多巴胺抵抗性微腺瘤型泌乳素瘤的患者管理策略
本文综述了多巴胺抵抗性微腺瘤型泌乳素瘤的临床管理。微腺瘤在绝经前女性中占比超过60%,多巴胺抵抗发生率低于10%,主要关注辅助生殖和妊娠期间肿瘤生长的风险,并讨论了代谢、骨质疏松和乳腺癌风险。
要点
- 微腺瘤型泌乳素瘤在绝经前女性中占比超过60%,通常无占位效应担忧。
- 多巴胺抵抗发生率低于10%,主要机制可能与多巴胺受体2亚型表达减少有关。
- 抵抗病例的主要关注点是辅助生殖技术和妊娠期间症状性肿瘤生长的风险。
核心结论
- 多巴胺抵抗性微腺瘤型泌乳素瘤需关注辅助生殖和妊娠期间肿瘤生长风险,理解抵抗机制可能开启新治疗策略。
研究设计与样本
- 综述类文章,检索范围未明确报告。
主要发现
- 微腺瘤型泌乳素瘤在绝经前女性中占比超过60%。
- 多巴胺抵抗发生率低于10%。
- 多巴胺受体2亚型表达减少被认为是抵抗的主要原因。
- 抵抗病例的主要关注点是辅助生殖技术和妊娠期间症状性肿瘤生长的风险。
关键数值与推荐
- 无症状或绝经后患者可期待管理。
- 存在性腺功能减退且无妊娠意愿时可用口服避孕药。
- 有困扰的溢乳、性腺功能减退且有生育意愿时使用多巴胺激动剂。
- 选择性非侵袭性病例可考虑神经外科手术。
临床怎么用
- 根据症状、生育意愿和绝经状态个体化选择管理策略。
- 对多巴胺抵抗患者,在辅助生殖和妊娠期间需监测肿瘤生长风险。
- 关注代谢参数、骨质疏松和乳腺癌风险等相关情况。
局限性
- 多巴胺抵抗的潜在机制尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prolactinoma is a significant cause of hyperprolactinemia and the most common type of pituitary tumor. Women of fertile age are most commonly affected, and the clinical picture is characterized by galactorrhea, oligo-amenorrhea, and infertility. In microprolactinomas, which represent more than 60% of cases in women before menopause, there is usually no concern about the mass effect. Therefore, management can be expectant if there are no symptoms or in a patient in the postmenopausal period; oral contraceptive in the presence of hypogonadism and no desire for pregnancy; dopamine agonist (DA) in the presence of bothersome galactorrhea, hypogonadism, and the desire for fertility; and neurosurgery in selected noninvasive cases. Resistance to DA occurs in less than 10% of cases. Although the reduction in dopamine receptor subtype 2 expression is considered the primary cause of DA resistance, the underlying mechanisms are not yet completely elucidated. The main concern in resistant cases is the risk of symptomatic tumor growth during assisted reproduction techniques and pregnancy. Other conditions in which hyperprolactinemia could be implicated, such as metabolic parameters, osteoporosis, and breast cancer risk are also discussed. Understanding the mechanisms of DA resistance can lead to the opening of new treatment strategies.
引用
- Glezer A, Stumpf MAM, Queiroz NL, et al. Approach to the Patient With Dopamine-Resistant Microprolactinoma. J Clin Endocrinol Metab. 2026. PMID: 41234156. doi:10.1210/clinem/dgaf624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。